文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

肠道微生物群在非酒精性脂肪性肝炎中的作用。

The Role of the Intestinal Microbiota in Nonalcoholic Steatohepatitis.

机构信息

Infectious Disease Department, Chongqing University Three Gorges Hospital, Chongqing, China.

Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China.

出版信息

Front Endocrinol (Lausanne). 2022 Feb 8;13:812610. doi: 10.3389/fendo.2022.812610. eCollection 2022.

DOI:10.3389/fendo.2022.812610
PMID:35211093
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8861316/
Abstract

Nonalcoholic steatohepatitis (NASH) is a serious disease threatening public health, and its pathogenesis remains largely unclear. Recent scientific research has shown that intestinal microbiota and its metabolites have an important impact on the development of NASH. A balanced intestinal microbiota contributes to the maintenance of liver homeostasis, but when the intestinal microbiota is disequilibrated, it serves as a source of pathogens and molecules that lead to NASH. In this review, we mainly emphasize the key mechanisms by which the intestinal microbiota and its metabolites affect NASH. In addition, recent clinical trials and animal studies on the treatment of NASH by regulating the intestinal microbiota through prebiotics, probiotics, synbiotics and FMT have also been briefly elaborated. With the increasing understanding of interactions between the intestinal microbiota and liver, accurate and personalized detection and treatment methods for NASH are expected to be established.

摘要

非酒精性脂肪性肝炎（NASH）是一种严重威胁公众健康的疾病，其发病机制在很大程度上尚不清楚。最近的科学研究表明，肠道微生物群及其代谢产物对 NASH 的发展有重要影响。平衡的肠道微生物群有助于维持肝脏内稳态，但当肠道微生物群失衡时，它就成为病原体和导致 NASH 的分子的来源。在这篇综述中，我们主要强调了肠道微生物群及其代谢产物影响 NASH 的关键机制。此外，我们还简要阐述了最近通过调节肠道微生物群来治疗 NASH 的临床研究和动物研究，这些方法包括使用益生元、益生菌、合生菌和 FMT。随着对肠道微生物群和肝脏之间相互作用的认识不断增加，有望建立针对 NASH 的精确和个性化的检测和治疗方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d93/8861316/f3b854e1132b/fendo-13-812610-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d93/8861316/f3b854e1132b/fendo-13-812610-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d93/8861316/f3b854e1132b/fendo-13-812610-g001.jpg

相似文献

[1]
The Role of the Intestinal Microbiota in Nonalcoholic Steatohepatitis.

Front Endocrinol (Lausanne). 2022

[2]
Review article: can bugs be drugs? The potential of probiotics and prebiotics as treatment for non-alcoholic fatty liver disease.

Aliment Pharmacol Ther. 2019-8-2

[3]
The Effects of Probiotics, Prebiotics and Synbiotics in Non-Alcoholic Fat Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH): A Systematic Review.

Int J Mol Sci. 2022-8-8

[4]
Microbiota and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH).

Ann Hepatol. 2019-4-16

[5]
Effect of Microbiome on Non-Alcoholic Fatty Liver Disease and the Role of Probiotics, Prebiotics, and Biogenics.

Int J Mol Sci. 2021-7-27

[6]
Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease Progression.

Crit Rev Oncog. 2020

[7]
Fighting Fatty Liver Diseases with Nutritional Interventions, Probiotics, Symbiotics, and Fecal Microbiota Transplantation (FMT).

Adv Exp Med Biol. 2019

[8]
Influence of gut microbiota on the development and progression of nonalcoholic steatohepatitis.

Eur J Nutr. 2017-9-5

[9]
Deciphering the role of gut metabolites in non-alcoholic fatty liver disease.

Crit Rev Microbiol. 2023-11

[10]
[Role of gut-liver-immune axis in the pathogenesis of nonalcoholic steatohepatitis].

Zhonghua Gan Zang Bing Za Zhi. 2021-6-20

引用本文的文献

[1]
Gut microbiota modulation by Traditional Chinese Medicine: a translational strategy for metabolic dysfunction-associated steatotic liver disease.

Front Pharmacol. 2025-6-10

[2]
Targeting Metabolism: Innovative Therapies for MASLD Unveiled.

Int J Mol Sci. 2025-4-25

[3]
Non-alcoholic fatty liver disease: Dietary and nutraceutical approaches.

Liver Res. 2023-8-25

[4]
sp. for the Attenuation of Metabolic Dysfunction-Associated Steatotic Liver Disease in Mice.

Microorganisms. 2024-12-3

[5]
Acupuncture, a Promising Therapy for Insulin Resistance and Non-Alcoholic Fatty Liver Disease.

Int J Gen Med. 2024-10-25

[6]
A Scoping Review on Hepatoprotective Mechanism of Herbal Preparations through Gut Microbiota Modulation.

Curr Issues Mol Biol. 2024-10-16

[7]
Impact of gut microbiota on metabolic dysfunction-associated steatohepatitis and hepatocellular carcinoma: pathways, diagnostic opportunities and therapeutic advances.

Eur J Med Res. 2024-10-5

[8]
Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases.

Front Cell Dev Biol. 2024-7-16

[9]
Implications of Microbiota and Immune System in Development and Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease.

Nutrients. 2024-5-29

[10]
Non-alcoholic Steatohepatitis in Asians: Current Perspectives and Future Directions.

Cureus. 2023-8-2

本文引用的文献

[1]
Gut Microbiota Reshaped by Pectin Treatment Improves Liver Steatosis in Obese Mice.

Nutrients. 2021-10-22

[2]
Dietary fiber-derived short-chain fatty acids: A potential therapeutic target to alleviate obesity-related nonalcoholic fatty liver disease.

Obes Rev. 2021-11

[3]
Hepatocyte-specific deletion of Nlrp6 in mice exacerbates the development of non-alcoholic steatohepatitis.

Free Radic Biol Med. 2021-6

[4]
The contribution of gut bacterial metabolites in the human immune signaling pathway of non-communicable diseases.

Gut Microbes. 2021

[5]
The NLRP3 inflammasome: Multiple activation pathways and its role in primary cells during ventricular remodeling.

J Cell Physiol. 2021-8

[6]
Imaging biomarkers of NAFLD, NASH, and fibrosis.

Mol Metab. 2021-8

[7]
Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention.

Nat Rev Gastroenterol Hepatol. 2021-4

[8]
A bridge for short-chain fatty acids to affect inflammatory bowel disease, type 1 diabetes, and non-alcoholic fatty liver disease positively: by changing gut barrier.

Eur J Nutr. 2021-8

[9]
Donor Fecal Microbiota Transplantation Alters Gut Microbiota and Metabolites in Obese Individuals With Steatohepatitis.

Hepatol Commun. 2020-10-7

[10]
Faecal microbiota transplantation halts progression of human new-onset type 1 diabetes in a randomised controlled trial.

Gut. 2021-1

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索